{"id":6355,"date":"2026-08-28T17:30:54","date_gmt":"2026-08-28T15:30:54","guid":{"rendered":"https:\/\/splmed.com\/?p=6355"},"modified":"2026-08-28T17:38:09","modified_gmt":"2026-08-28T15:38:09","slug":"cost-effectiveness-of-ferumoxtran-enhanced-macrophage-specific-mri-and-psma-pet-ct-versus-eplnd-for-nodal-staging-in-primary-prostate-cancer-a-decision-analysis-based-on-updated-phase-3-trial-data","status":"publish","type":"post","link":"https:\/\/splmed.com\/english\/cost-effectiveness-of-ferumoxtran-enhanced-macrophage-specific-mri-and-psma-pet-ct-versus-eplnd-for-nodal-staging-in-primary-prostate-cancer-a-decision-analysis-based-on-updated-phase-3-trial-data\/","title":{"rendered":"Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET\/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data"},"content":{"rendered":"<p class=\"p1\"><b>Background and objective: <\/b>Accurate nodal staging in intermediate- to high-risk prostate cancer (PCa) is crucial for treatment decisions. While extended pelvic lymph node dissection (ePLND) is the standard, it is invasive and has a low diagnostic yield. A 2019 analysis suggested that non-invasive imaging such as PSMA-PET\/CT and ferumoxtran-enhanced macrophage-MRI (m-MRI) is cost-effective, but at the possible expense of a small QALY loss compared to ePLND, based on limited evidence. Recent Phase 3 trials have provided new data, prompting a reevaluation. Therefore, the aim of this article is to update a model with recent trial data to &#8230;<\/p>\n<p><a href=\"https:\/\/splmed.com\/wp-content\/uploads\/2026\/03\/PRESS-RELEASE-MAA-Vf.pdf\">https:\/\/splmed.com\/wp-content\/uploads\/2026\/08\/Cost-effectiveness-of-ferumoxtran-enhanced-macrophage-specific-MRI-and-PSMA-PET-CT-versus-ePLND-for-nodal-staging-in-primary-prostate-cancer-a-decisi.pdfhttps:\/\/splmed.com\/wp-content\/uploads\/2026\/03\/PRESS-RELEASE-MAA-Vf.pdf<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Background and objective: Accurate nodal staging in intermediate- to high-risk prostate cancer (PCa) is crucial for treatment decisions. While extended pelvic lymph node dissection (ePLND) is the standard, it is invasive and has a low diagnostic yield. A 2019 analysis suggested that non-invasive imaging such&#8230;<\/p>","protected":false},"author":2,"featured_media":6359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-6355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/comments?post=6355"}],"version-history":[{"count":1,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6355\/revisions"}],"predecessor-version":[{"id":6357,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6355\/revisions\/6357"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/media\/6359"}],"wp:attachment":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/media?parent=6355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/categories?post=6355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/tags?post=6355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}